I had the privilege of speaking with Dr. Bruce Werber about the innovative use of placental tissue allografts in regenerative medicine. With 35 years of experience as a board-certified foot and ankle surgeon, Dr. Werber also serves as the COO of BioTech Products, Services, and Research (BPSR) and the CEO of its subsidiary, Anu Life Sciences.
BioInformant's Founder, Cade Hildreth, has interviewed hundreds of key opinion leaders (KOL's) from across the stem cell industry.
Celularity – Big Bucks, Billionaire Investors, Bold Dreams
Celularity is a biotechnology company that specializes in leveraging biologically active cell populations within the postpartum human placenta. Founded on the pioneering work of Robert Hariri, MD, PhD, in human placenta-derived cellular therapeutics and biomaterials, Celularity is uniquely positioned to harness the potential of most biocreative event on earth: human birth. [Read more…]
Dr. Chris Centeno, Visionary Behind Regenexx® Stem Cell Technology
Dr. Chris Centeno is an international expert in regenerative medicine and the clinical use of mesenchymal stem cells (MSCs) for orthopedic applications. This is Part 2 of an interview with Dr. Centeno.
Read Part 1 of the interview here.
ACL Surgeries and Regenexx Stem Cell Technology
Dr. Centeno specializes in clinical use of adult stem cells for orthopedic injuries, which he treats through same-day procedures at his clinic in Denver, Colorado, and through cultured expansion of mesenchymal stem cells at a clinic in Grand Cayman. He first performed these adult stem cell procedures in the U.S. in 2005-2006, and his clinic has since has treated thousands orthopedic patients with stem cell based therapies.
Dr. Chris Centeno is best known for the Regenexx® technology, an approach that uses needle-based procedures coupled with sophisticated guidance techniques to place large numbers of stem cells at the site needing repair. This approach can often replace the need for invasive orthopedic surgeries. [Read more…]
Dr. Robert Hariri on Cell Therapeutics, Combination Therapies, and COVID-19
With greater than 30 million cases and 946,000 deaths reported from COVID-19 worldwide, the novel Coronavirus represents one of the largest pandemics in modern history. Thankfully, it also represents the largest cooperative effort in human history.
Globally, scientists are exploring every potential weapon to suppress the threat, including vaccines, repurposed drugs, combination therapies, and as we explore here, cellular therapies with promising cell types such as natural killer (NK) cells and mesenchymal stem cells (MSCs).
In this interview with Dr. Robert Hariri, CEO of Celularity, Inc., we discuss the company’s cell therapeutics pipeline against COVID-19. Enjoy! [Read more…]
Growth Rates & Trends within the Cord Blood Industry – Interview with Kenneth Harris
The cord blood banking industry is often surrounded by misleading metrics, making insights from experts especially valuable. In an interview with Kenneth Harris, Chief Advisor for CuraSense Advisors, we delve into his extensive knowledge of the field. The discussion covers global growth rates, key trends shaping the industry, geographic differences in opportunities, and more, providing a comprehensive look at this evolving sector.
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 15
- Next Page »